335 related articles for article (PubMed ID: 18056833)
1. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
[TBL] [Abstract][Full Text] [Related]
2. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
3. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
Cummings JL; Mackell J; Kaufer D
Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
7. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
Grossberg GT; Pejović V; Miller ML; Graham SM
Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
[TBL] [Abstract][Full Text] [Related]
8. A 6-month, open-label study of memantine in patients with frontotemporal dementia.
Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A
Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609
[TBL] [Abstract][Full Text] [Related]
9. Memantine in the treatment of dementia.
Maggiore C; Locatelli L; Grandi FC; Pizzolato G;
Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774
[No Abstract] [Full Text] [Related]
10. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
11. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community.
Matsumoto N; Ikeda M; Fukuhara R; Shinagawa S; Ishikawa T; Mori T; Toyota Y; Matsumoto T; Adachi H; Hirono N; Tanabe H
Dement Geriatr Cogn Disord; 2007; 23(4):219-24. PubMed ID: 17299264
[TBL] [Abstract][Full Text] [Related]
12. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease.
Okahara K; Ishida Y; Hayashi Y; Inoue T; Tsuruta K; Takeuchi K; Yoshimuta H; Kiue K; Ninomiya Y; Kawano J; Yoshida K; Noda S; Tomita S; Fujimoto M; Hosomi J; Mitsuyama Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):532-6. PubMed ID: 20170698
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
14. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
15. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
Paleacu D; Barak Y; Mirecky I; Mazeh D
Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
[TBL] [Abstract][Full Text] [Related]
16. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.
Rüther E; Glaser A; Bleich S; Degner D; Wiltfang J
Pharmacopsychiatry; 2000 May; 33(3):103-8. PubMed ID: 10855461
[TBL] [Abstract][Full Text] [Related]
17. Memantine for dementia?
Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
[TBL] [Abstract][Full Text] [Related]
18. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
Görtelmeyer R; Erbler H
Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054
[TBL] [Abstract][Full Text] [Related]
19. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
